User login
Key clinical point: Age, body mass index (BMI), chronic-plaque psoriasis, hospitalization for psoriasis, use of systemic therapy, and genital and nail involvement in psoriasis were the risk factors for psoriatic arthritis (PsA) occurrence in patients with psoriasis.
Major finding: Overall, 226 patients were diagnosed with PsA, with an incidence of 1.9 cases per 100 patient-years. Age between 40-59 years (P < .001), BMI ≥25 (P = .015), genital psoriasis (P = .027), nail psoriasis (P = .038), classic chronic-plaque psoriasis (P = .014), previous hospitalization for psoriasis (P < .001), previous use of systemic therapy for psoriasis (P = .003), and use of conventional nonbiologic agents (P = .014) were significantly associated with PsA occurrence.
Study details: This cohort study included 8895 patients with a confirmed diagnosis of psoriasis from the PsoReal registry.
Disclosures: This study was sponsored by Bristol Myers Squibb. K Heidemeyer and L Naldi declared receiving honoraria from various sources, including AbbVie, Almirall, or Bristol Myers Squibb.
Source: Heidemeyer K et al. Variables associated with joint involvement and development of a prediction rule for arthritis in psoriasis patients. An analysis of the Italian PsoReal database. J Am Acad Dermatol. 2023 (Mar 23). Doi: 10.1016/j.jaad.2023.02.059
Key clinical point: Age, body mass index (BMI), chronic-plaque psoriasis, hospitalization for psoriasis, use of systemic therapy, and genital and nail involvement in psoriasis were the risk factors for psoriatic arthritis (PsA) occurrence in patients with psoriasis.
Major finding: Overall, 226 patients were diagnosed with PsA, with an incidence of 1.9 cases per 100 patient-years. Age between 40-59 years (P < .001), BMI ≥25 (P = .015), genital psoriasis (P = .027), nail psoriasis (P = .038), classic chronic-plaque psoriasis (P = .014), previous hospitalization for psoriasis (P < .001), previous use of systemic therapy for psoriasis (P = .003), and use of conventional nonbiologic agents (P = .014) were significantly associated with PsA occurrence.
Study details: This cohort study included 8895 patients with a confirmed diagnosis of psoriasis from the PsoReal registry.
Disclosures: This study was sponsored by Bristol Myers Squibb. K Heidemeyer and L Naldi declared receiving honoraria from various sources, including AbbVie, Almirall, or Bristol Myers Squibb.
Source: Heidemeyer K et al. Variables associated with joint involvement and development of a prediction rule for arthritis in psoriasis patients. An analysis of the Italian PsoReal database. J Am Acad Dermatol. 2023 (Mar 23). Doi: 10.1016/j.jaad.2023.02.059
Key clinical point: Age, body mass index (BMI), chronic-plaque psoriasis, hospitalization for psoriasis, use of systemic therapy, and genital and nail involvement in psoriasis were the risk factors for psoriatic arthritis (PsA) occurrence in patients with psoriasis.
Major finding: Overall, 226 patients were diagnosed with PsA, with an incidence of 1.9 cases per 100 patient-years. Age between 40-59 years (P < .001), BMI ≥25 (P = .015), genital psoriasis (P = .027), nail psoriasis (P = .038), classic chronic-plaque psoriasis (P = .014), previous hospitalization for psoriasis (P < .001), previous use of systemic therapy for psoriasis (P = .003), and use of conventional nonbiologic agents (P = .014) were significantly associated with PsA occurrence.
Study details: This cohort study included 8895 patients with a confirmed diagnosis of psoriasis from the PsoReal registry.
Disclosures: This study was sponsored by Bristol Myers Squibb. K Heidemeyer and L Naldi declared receiving honoraria from various sources, including AbbVie, Almirall, or Bristol Myers Squibb.
Source: Heidemeyer K et al. Variables associated with joint involvement and development of a prediction rule for arthritis in psoriasis patients. An analysis of the Italian PsoReal database. J Am Acad Dermatol. 2023 (Mar 23). Doi: 10.1016/j.jaad.2023.02.059